Aglycosyl anti- CD154 (CD 40 ligand) antibodies and uses thereof

A -CD154, antibody technology, applied in the field of aglycosyl anti-CD154 antibody or its antibody derivative, can solve the problem of inappropriate platelet activation and the like

Active Publication Date: 2006-09-20
BIOGEN IDEC MA INC
View PDF13 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the mechanism of this side effect is unknown, it may involve the aggregation of FcgRIIa and CD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aglycosyl anti- CD154 (CD 40 ligand) antibodies and uses thereof
  • Aglycosyl anti- CD154 (CD 40 ligand) antibodies and uses thereof
  • Aglycosyl anti- CD154 (CD 40 ligand) antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0156] Example 1: Generation and evaluation of the aglycosyl hu5c8 antibody

[0157] Production and expression of aglycosyl hu5c8 mAb

[0158] To reduce the effector function of hu5c8 mAb, the aglycosylated form was modified by changing the heavy chain C H2 The classical N-linked Asn site in the domain was created for the Gln residue.

[0159] Competition binding assays confirmed that the ability of aglycosylated hu5c8 mAb to bind cell surface CD154 was not altered compared to glycosylated hu5c8 mAb ( figure 1 ).

[0160] Effector function was assayed in vitro using a bridging assay format. Compared with glycosylated hu5c8 mAb, the relative binding of aglycosylated hu5c8 mAb to FcγRI was reduced by 25-fold ( figure 2 A). Residual binding of aglycosylated hu5c8 mAb to FcγRIII could not be demonstrated at concentrations up to 5 mg / ml, whereas normally glycosylated hu5c8 mAb showed an EC50 of 50 ng / ml in the same assay format ( figure 2 B).

[0161] Pharmacokinetics of a...

Embodiment 2

[0173] Example 2: Aglycosyl hu5c8 antibody inhibits initial and subsequent humoral responses

[0174] Suppression of the initial humoral immune response to tetanus toxoid (TT) antigen in macaques

[0175] The ability of aglycosylated hu5c8 mAb and glycosylated hu5c8 mAb (prepared according to Example 1 ) to inhibit the initial antibody response to TT, each at a single dose of 20 mg / kg, was assessed in separate experiments. Administration of aglycosylated hu5c8 mAb or glycosylated hu5c8 mAb resulted in an overall primary immune response compared to saline-treated controls (E AUC ) were reduced by 70% and 77%, respectively. Figure 4 Graph showing TT antibody titers throughout 42 days, showing that aglycosylated hu5c8 mAb inhibits initial humoral responses to a similar extent as glycosylated hu5c8 mAb, but with reduced FcγR binding.

[0176] The immunogenicity of humanized mAbs is another measure of their effectiveness in this non-human primate model. Three of four animals tr...

Embodiment 3

[0197] Example 3: Aglycosyl muMR1 antibody inhibits lupus nephritis

[0198] Systemic lupus erythematosus ("SLE") is a spontaneously occurring autoimmune disease, predominantly in women, characterized by the production of multiple pathological antinuclear autoantibodies. In lupus nephritis, renal injury is primarily mediated by a combination of cellular and humoral immune mechanisms, including the formation of immune complexes that deposit in glomeruli and activate the complement cascade, which leads to glomerulonephritis. It was previously determined that antinuclear antibody production in both human and mouse SLE is driven by cognate interactions between selected populations of autoimmune Th and B cells. [Kalled et al., 1998].

[0199] Previous studies demonstrated that chronic treatment of hamster MR1 (haMR1) with an anti-CD154 mAb in (SWR x NZB) F1(SNF1) mice with established lupus nephritis prolongs survival and reduces Incidence of severe nephritis.

[0200] In this e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune response with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.

Description

technical field [0001] The present invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives thereof, which block the interaction of CD154 and CD40 molecules. In addition, the present invention provides methods for preparing aglycosyl anti-CD154 antibodies and antibody derivatives. The antibodies and antibody derivatives of the present invention are useful in the treatment and prevention of diseases associated with unwanted immune responses, as well as diseases mediated by CD154-CD40 interactions. Background technique [0002] The generation of humoral and cell-mediated immunity is the result of the interaction of activated helper T cells with antigen presenting cells ("APCs") and effector T cells. Activation of helper T cells not only depends on the interaction of antigen-specific T cell receptors ("TCRs") with their corresponding peptide-MHC ligands, but also requires the cooperative binding and activation of various cell adhesion molecules and co-stimu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28A61K39/395C12N5/10
CPCY02A50/30
Inventor 弗雷德里克·R·泰勒克里斯托弗·D·本杰明琳达·C·伯克利埃伦·A·加伯
Owner BIOGEN IDEC MA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap